Biosulin R, 100 me/ml 3 ml cartridges 5 pcs

Biosulin P, short-acting insulin, is human insulin produced using recombinant DNA technology.

It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, stimulating intracellular processes including synthesis of several key enzymes (hexokinase, pyruvate kinase, glycogen synthetase).

Lower blood glucose content is due to increased intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis and glycogenogenesis and decreased rate of glucose production by liver.

The duration of action of Biosulin P is mainly determined by the rate of absorption, which depends on several factors (such as dose, route and place of administration) and therefore the action profile of insulin is subject to significant variations both in different people and in the same person.

After p/q administration, the onset of action of Biosulin R is observed in approximately 30 min, the maximum effect is between 2 and 4 h, the duration of action is 6-8 h.

Indications

– diabetes mellitus type 1 (insulin dependent);
– diabetes mellitus type 2 (insulin-independent): stage of resistance to oral hypoglycemic drugs, partial resistance to these drugs (during combined therapy), intercurrent diseases.
– emergency conditions in patients with diabetes mellitus, accompanied by decompensation of carbohydrate metabolism

.

Composition

1 ml of injectable solution contains:

the active ingredient:

Human isophane insulin 100 units;

auxiliary substances:

glycerol;

metacresol;

water for injection

How to take, the dosage

The dose of Biosulin R is determined by the physician individually, in each case on the basis of blood glucose levels.

The drug is intended for infusion.

The average daily dose varies from 0.5 to 1 IU/kg of body weight (depending on the individual patient and blood glucose level)

Interaction

There are a number of medications that affect the need for insulin.

. Hypoglycemic effect of insulin is enhanced by oral hypoglycemic drugs, MAO inhibitors, non-selective beta-adrenoblockers, ACE inhibitors, sulfonamides, anabolic steroids, carbohydrase inhibitors, bromocriptine, octreotide, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, phenfluramine, lithium preparations, preparations containing ethanol.

Hypoglycemic effect of insulin is reduced by oral contraceptives, GCS, thyroid hormones, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, danazol, clonidine, calcium channel blockers, diazoxide, morphine, phenytoin, nicotine.

Reserpine and salicylates may both weaken and enhance the effect of the drug.

Special Instructions

Biosulin P should not be used if the suspension does not turn white and uniformly turbid after shaking.

In insulin therapy, continuous monitoring of blood glucose levels is necessary.

Contraindications

– hypoglycemia;
– hypersensitivity to insulin or other components of Biosulin N.

Side effects

Metabolic disorders: hypoglycemic states (pale skin, increased sweating, palpitations, tremors, hunger, agitation, paresthesias in the mouth, headache).

Severe hypoglycemia may lead to hypoglycemic coma.

Allergic reactions: rarely – skin rash, Quincke’s edema; in some cases – anaphylactic shock.

Local reactions: hyperemia, swelling and itching at the injection site; with long-term use – lipodystrophy at the injection site.
Other: edema, transient refractive disorders (usually at the beginning of therapy).

Overdose

Symptoms: hypoglycemia may occur.

Treatment: mild hypoglycemia can be eliminated by the patient himself by taking sugar or carbohydrate-rich foods (diabetics are recommended to carry sugar, sweets, cookies or sweet fruit juice at all times).

In severe cases, in case of loss of consciousness – IV infusion of 40% dextrose solution; intravenous, p/c or intravenous – glucagon.

After restoration of consciousness, the patient is advised to take a carbohydrate-rich meal to prevent the recurrence of hypoglycemia.

Pregnancy use

There are no data on the use of the drug in pregnancy and during breast-feeding.